Sign in with Google. Opens in new tab
bullish
Samsung BioLogics (207940 KS): Korea FSC Ruling Summary & Clarifications
913 Views12 Jul 2018 17:56
This Korea FSC's final ruling on Samsung Biologics Co., Ltd (207940 KS)'s accounting fraud case is very confusing. So, let me walk you...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- Nikkei 225 Index Rebalance: Rohm (6963) To Replace NTT Data Group (9613)
- [Quiddity Index] Nikkei 225 Boots NTT Data (9613) Early, Rohm (6963) IN 3 July; $3.8bn a Side
- Last Week in Event SPACE: Shin Kong/Taishin, Santos, NTT Data, ENN Energy, Mitsui Matsushima
- China Healthcare Weekly (Jun.22) - CNPGC to Acquire Shuanglin, Thoughts on Zhou Liu Fu's IPO Pricing
- Sysmex Corp (6869 JP): Forex to Take Some Sheen Away off Growth in FY26; Japan Still Remains Key
Top Unpaywalled Insights
More »- [IO Technicals 2025/25] Bearish Momentum Strengthens
- VEON (VEON US): Launches Third Phase of Share Buyback Program After Share Pullback
- Valuations, Visas & Venture Pullback: An Equity + M&A Overview of the Education Sector in Q1 2025
- Overview #27 – The Big Beautiful Tragi-Comedy Continues
- HK Connect SOUTHBOUND Flows (To 13 June 2025); Volumes Up, TECH Down, HEALTHCARE Bought Big
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Korea Top Conglomerates Synthetic Pair Trading20 May 2021
- Samsung Biologics Contract Manufacturing Deal with Moderna for COVID-19 Vaccines: Key Takeaways14 May 2021
- Samsung Biologics CMO Deal Noise & Samsung C&T Synthetic Subsidiary Stub Trade12 May 2021
- Samsung BioLogics (207940 KS): Korea FSC Ruling Summary & Clarifications12 Jul 2018
- Biogen Exercises Samsung Bioepis Call Option - Summary & Implications29 Jun 2018
- FSS Vs. Samsung BioLogics - Latest Situation Update09 May 2018
- Samsung BioLogics - Market Sentiment Assessment05 May 2018
x